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The collagenase subfamily of matrix metalloproteinases
(MMPs) have important roles in the remodeling of collagenous
matrices. The proteinase-activated receptor (PAR) family has a
unique mechanism of activation requiring proteolysis of an
extracellular domain forming a neo-N terminus that acts as a
tethered ligand, a process that has been associated with the
development of arthritis. Canonical PAR2 activation typically
occurs via a serine proteinase at Arg36-Ser37, but other protei-
nases can cleave PARs downstream of the tethered ligand and
“disarm” the receptor. To identify additional cleavage sites
within PAR2, we synthesized a 42-amino-acid peptide corre-
sponding to the extracellular region.We observed that all three
soluble MMP collagenases, MMP-1, MMP-8, and MMP-13,
cleave PAR2 and discovered a novel cleavage site (Ser37-Leu38).
Metalloproteinases from resorbing bovine nasal cartilage and
recombinant human collagenases could cleave a quenched fluo-
rescent peptide mimicking the canonical PAR2 activation
region, and kinetic constants were determined. In PAR2-over-
expressing SW1353 chondrocytes, we demonstrated that the
activator peptide SLIGKV-NH2 induces rapid calcium flux,
inflammatory gene expression (includingMMP1 andMMP13),
and thephosphorylationof extracellular signal-regulatedkinase
(ERK) and p38 kinase. The corresponding MMP cleavage-de-
rived peptide (LIGKVD-NH2) exhibited no canonical activation;
however, we observed phosphorylation of ERK, providing evi-
dence of biased agonism. Importantly, we demonstrated that
preincubation with active MMP-1 reduced downstream PAR2
activation by a canonical activator,matriptase, but not SLIGKV-
NH2.These results support a role for collagenases as proteinases
capable of disarming PAR2, revealing a mechanism that sup-
presses PAR2-mediated inflammatory responses.
Proteinases are enzymes that effect proteolysis of intact pro-
teins via the hydrolysis of peptide bonds (1) and are essential in
a myriad of situations in both health and disease such as extra-
cellular matrix (ECM)3 remodeling during development or
pathological destruction. In humans, almost two-thirds of the
proteinases that comprise the degradome (2) exert their activ-
ities within the extracellular space, making them prime candi-
dates in events that entail remodeling and/or degradation of the
ECM. These can be subdivided into metallo- and serine protei-
nases, and in this context these proteinases have until recently
been viewed as mediating the proteolytic degradation of ECM
components as occurs for example in tumor invasion or arthri-
tis. However, it is now clear that proteinases also perform pre-
cise and specific functions in both homeostasis and disease. The
cleavage of triple-helical collagens such as type II collagen (the
major structural component present in cartilage) by the soluble
collagenase subset of matrix metalloproteinases (MMP-1,
MMP-8, and MMP-13) represents an example of highly spe-
cific proteolysis whereby only a single peptide bond is cleav-
able under normal physiological conditions (3). This initial
cleavage then leads to collagen denaturation, concomitant
with increased susceptibility to other less specific protei-
nases and disassembly of the collagen network, which is a
requirement as cartilage is remodeled into bone during
development, but also occurs during cartilage breakdown in
degenerative scenarios such as rheumatoid arthritis and
osteoarthritis (OA).
Proteinase-activated receptors (PARs) represent one mech-
anism by which proteinases can delicately regulate cellular
responses and are likely to be involved in many disease pro-
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cesses. The importance of PAR2 in the pathogenesis of both
inflammatory arthritis andOAhas recently emerged, andPAR2
deficiency provides protection in experimental arthritismodels
(4–9). We have demonstrated that an activator of PAR2,
matriptase, induces cartilage destruction in a PAR2- and
metalloproteinase-dependent manner (10, 11) and that a
related serine proteinase, hepsin, can also activate PAR2, albeit
in a markedly less efficient manner (12). Indeed, in complex
disease environments (such as arthritis) multiple proteinases
could be present to act on PAR2, making our understanding of
how PAR2 is activated and regulated important (for a review,
see Ref. 13).
PAR2 exhibits receptor plasticity with biased signaling, dif-
ferent proteinases eliciting different downstream responses fol-
lowing cleavage of the extracellular domain, which may be of
particular importance in modulating inflammatory responses
(see Refs. 14 and 15). Here, we investigated the effect of collag-
enolytic MMPs, known to be expressed during ECM remodel-
ing events (16), on PAR2. We identified novel cleavages by
MMP-1, -8, and -13, and a primary cleavage site common to all
was identified. Collagenase cleavage resulted in antagonism of
PAR2 activation, suggesting an important negative feedback
mechanism whereby canonical PAR2 activation induces MMP
expression, and MMP activity can subsequently antagonize
PAR2.
Results
MMP collagenases cleave the PAR2 extracellular domain
To determine which collagenolytic MMPs can cleave the
extracellular PAR2 sequence, we synthesized a 42-amino-acid
peptide, corresponding to the N-terminal extracellular region
of PAR2 (PAR231–72 peptide) where previous PAR2 cleavage
sites have been identified (17–19) (Fig. 1A). After confirming
the peptide was cleaved by known PAR2-cleaving protei-
nases (Fig. 1B), the peptide was incubated with APMA-acti-
vated MMP-1, MMP-8, and MMP-13. Silver-stained SDS-
PAGE gels of the digested products demonstrated that all
three collagenases were capable of cleaving this sequence in
a dose-dependent manner (Fig. 1C). Cleavage was subse-
quently confirmed by reverse-phase HPLC (Fig. 2, A–C), and
peaks were collected and subjected to electrospray mass
spectrometry (MS). Exact mass identifications revealed
cleavage sites for each collagenase (Fig. 2D), but interest-
ingly, time-course experiments identified a primary cleavage
common to all, following Ser37 (Fig. 3). This novel site is
adjacent to the canonical cleavage site described for trypsin-
like serine proteinases, Arg36.
Collagenases cleave a PAR2 synthetic peptide substrate
To further explore and determine kinetic constants for col-
lagenase cleavage of PAR2, a quenched fluorescent peptide
Figure 1. The collagenases are able to cleave the PAR2 extracellular domain. A 42-amino-acid peptide corresponding to Arg31–Lys72 of the extracellular
domain of PAR2 (denoted in red) was produced. Various known cleavage sites are highlighted: the canonical activation site (trypsin, matriptase, etc., with the
tethered ligand/activator peptide sequence underlined); CS, cathepsin S; PR3, proteinase 3; CG, cathepsin G;NE, neutrophil elastase (A). The PAR231–72 peptide
(10M)was incubatedwith 10nMhepsinor elastase, 1 nM cathepsinG, or 0.1 nMmatriptase for the indicateddurationsbefore resolvingon20%polyacrylamide
gels utilizing a Tris-Tricine buffer systemand silver staining. S, substrate; P, product. Presented gels are representative of at least two independent experiments
(B). The PAR231–72 peptide (10 M) was incubated with increasing concentrations of APMA-activated recombinant pro-MMP-1, -8, and -13 for 24 h before
resolving on 20%polyacrylamide gels utilizing a Tris-Tricine buffer system and silver staining. S, substrate; P, product. The presented gels are representative of
three independent experiments (C).
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mimic of PAR2was employed (2-Abz-SKGRSLIG-Y(NO2)). To
demonstrate cleavage by native MMPs, the peptide was incu-
bated with conditioned medium from 14-day IL-1OSM-
stimulated bovine nasal cartilage, a well-established model of
proteinase-driven cartilage breakdown (10, 20, 21). Cleavage
was observed; however, this was completely abolished by the
addition of the MMP inhibitor GM6001 but not by serine or
cysteine proteinase inhibition (Fig. 4A). Subsequently, recom-
binant APMA-activated MMP-1, -8, and -13 were shown to
cleave the peptide, with the effect dependent on active-site
accessibility (Fig. 4B). Velocity was calculated from progress
curves at variable concentrations of substrate, and the resultant
plots are consistent with each collagenase exhibiting Michaelis–
Menten kinetics (Fig. 4C). APMA-activated MMP-1, MMP-8,
and MMP-13 exhibited similar Km values for this substrate,
36–53 M, which are similar to that of matriptase (46.6 M).
MMP-13 exhibited the highest turnover number (kcat) of all
three collagenases and therefore the highest catalytic efficiency
(kcat/Km), although this was markedly lower than that of
matriptase (Fig. 4D).
Canonical PAR2 activation induces collagenolytic MMP
expression
To generate a model of chondrocytes expressing higher
levels of PAR2 (as is the case in OA (22, 23)), we overexpressed
PAR2 using a lentivirus transduction system. SW1353
cells transduced with a PAR2-expressing lentivirus (hereafter
SW1353-PAR2; dependence of PAR2 expression validated in
Fig. S1) were stimulated with the PAR2 activator peptide
SLIGKV-NH2, which resulted in calcium mobilization (Fig.
5A). Furthermore, stimulation for varying durations resulted in
ATF3, MMP1, and MMP13 gene expression (Fig. 5, B and C).
ATF3 is a transcription factor we recently identified as regulat-
ing MMP13 expression following cytokine stimulation (24).
Secreted MMP-1 and MMP-13 were subsequently detected in
the culture medium 48 h poststimulation (Fig. 5D).
The N terminus generated by collagenase cleavage does not
activate canonical PAR2 signaling
Due to the proximity of the primary collagenase cleavage site
to the canonical PAR2 activation sequence, the effect of the
Figure 2. TheMMPcollagenases cleavePAR2at anovel site. The PAR231–72 peptide (10M)was incubatedwithAPMA-activatedMMP-1 (400 nM;A), MMP-8
(20 nM; B), or MMP-13 (200 nM; C) for 24 h, and reversed-phase HPLC was performed. HPLC chromatograms are representative of at least two independent
experiments and are presented as separate graphs for clarity with the same control chromatogram presented in each panel. Peaks identified by HPLC were
collected and subjected to further analysis by electrosprayMS,which identifiedMMP-derived cleavage sites at Ser37-Leu38 andVal68-Leu69, to reveal a putative
neoepitope-tethered ligand (underlined in D). The colored arrows (A–C) and lines (D) indicate the following: red, parent peptide; green, Ser37-Leu38 cleavage;
amber, Val68-Leu69 cleavage; blue, Ser37-Leu38 and Val68-Leu69 cleavage. Observed masses are presented in Table S1.mAU, milli-absorbance units.
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resultant neo-N terminus on PAR2 activation was investigated
by synthesizing a peptide corresponding to the putative teth-
ered ligand, LIGKVD-NH2 (see Fig. 2D). SW1353-PAR2 cells
stimulated with LIGKVD-NH2 or the control reverse peptide
(DVKGIL-NH2) exhibited no calciummobilization (Fig. 6A) or
the expression of ATF3 orMMP1 (Fig. 6B).
The collagenase-derived PAR2 peptide LIGKVD-NH2 induces
biasedmitogen-activated protein kinase (MAPK)
phosphorylation
MAPK phosphorylation is a well-characterized downstream
output of canonical PAR2 activation (25–27). Indeed, hereinwe
confirm that SLIGKV-NH2 (Fig. 6C) induces phosphorylation
of ERK and p38 at early time points. Intriguingly, LIGKVD-
NH2 induced ERK but not p38 phosphorylation (Fig. 6D),
whereas the control reverse peptide did not markedly induce
either MAPK (Fig. 6E).
Collagenase cleavage antagonizes PAR2
Todetermine the effect of collagenase cleavage on the poten-
tial for PAR2 to be subsequently activated by canonical
PAR2 activators, we performed preincubation experiments.
When recombinant active MMP-1 was preincubated with
SW1353-PAR2 cells, matriptase-induced PAR2 activation
was abrogated, but importantly, activation by SLIGKV-NH2
was not (Fig. 7A). There was no evidence of ATF3 induction
byMMP-1 on either SW1353 control cells or SW1353-PAR2
cells (Fig. 7B). SW1353-PAR2 cells preincubated with LIG-
Figure 3. Time course of PAR231–72 cleavage by MMP-13. PAR231–72 peptide (10 M) was incubated with APMA-activated pro-MMP-13 (200 nM) over
a 24-h time course as indicated (A–D), and reversed-phase HPLC was performed. Arrows indicate identity of observed peaks: red, parent peptide; green,
Ser37-Leu38; blue, Ser37-Leu38  Val68-Leu69. Presented HPLC chromatograms are representative of three independent experiments. mAU, milli-absor-
bance units.
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KVD-NH2 markedly reduced the capacity for canonical acti-
vation by the SLIGKV-NH2 (Fig. 7C), whereas cells preincu-
bated with the control reverse peptide did not (Fig. 7D).
Discussion
It is becoming increasingly clear that proteolysis not only
mediates catabolic events but can also act to precisely regulate
cellular processes. One such example, the PARs, represent a
way in which controlled cleavage of a substrate by different
proteinases leads to different downstream events and out-
comes. In this study, we outline such regulation of PAR2 by a
family of proteinases that, to our knowledge, have not been
investigated before in this context. We demonstrated that the
collagenasesMMP-1, -8, and -13 can cleave the PAR2 extracel-
lular region, with MMP-1 yielding a single product resulting
from cleavage at Ser37-Leu38 with an additional cleavage at
Val68-Leu69 observed following MMP-8 and -13 incubations.
These cleavage sites are in agreement with the described sub-
strate specificities of the collagenases, which show a preference
for a hydrophobic residue in the P1 position, a basic or hydro-
phobic amino acid in the P2 position, and a small amino acid in
the P3 position (28–30). Thus, the Ser37-Leu38 site fits this
preference with leucine, isoleucine, and glycine in P1–P3,
respectively, whereas the Val68-Leu69 site fits at the P1 and P3
positions (leucine and glycine, respectively). Taken together
with time-course experiments, it is likely that Ser37-Leu38 is the
primary collagenase cleavage site on PAR2. It remains possible,
however, that both cleavages could hold functional relevance.
For example, following canonical PAR2 activation by mast cell
tryptase, signaling has been shown to be attenuated by a sec-
ondary downstream cleavage (31).
Figure 4. The collagenases cleave PAR2with varying efficiencies. 2-Abz-SKGRSLIG-Y(NO2) peptide (10M) was incubated with day 14 conditionedmedia
from IL-1OSM-stimulated bovine nasal cartilage explant cultures in the presence or absence of 100MGM6001, 10M E64, or 2mMdiisopropyl fluorophos-
phate (DFP). Data (mean  S.D.) are normalized to the no-inhibitor control sample and are representative of at least two independent experiments with
conditionedmedia fromdifferent cartilages (A). 2-Abz-SKGRSLIG-Y(NO2)peptide (50M)was incubatedwithAPMA-activated recombinantpro-MMP-1 (50nM),
-8 (10 nM), or -13 (20 nM) in the presence or absence of 50 M GM6001 or DMSO-only control, and data were normalized to the inhibitor/DMSO negative sample
(mean S.D.), combiningmeans (each with n 2 technical replicates) from four independent experiments (B). Michaelis–Menten curves (mean S.D.; presented
graphs show combined means (each with n 2 technical replicates) of three independent experiments) were generated using TIMP-1–titrated APMA-activated
recombinant pro-MMP-1, -8, and -13 (C). The hydrolysis of substrate was quantified (nMs1) using a standard curve determined by total substrate hydrolysis, and
nonlinear regressionanalysiswasperformedtogeneratekinetic constantsKmandVmax.kcatwas subsequently calculated fromVmaxandactiveenzymeconcentration.
Tabulatedkineticconstants (meanS.D.)are fromthree independentexperiments.Matriptasekineticparametersare includedforcomparison(D). Selectedstatistical
comparisonswere performed using Student’s two-tailed unpaired t tests where *** indicates p 0.001. All error bars represent S.D.
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The kinetic profiles of PAR2 cleavage by the collagenases
were explored and compared with matriptase, a potent activa-
tor of PAR2 (12). Unsurprisingly, all three collagenases were
less efficient at cleaving the substrate compared with matrip-
tase (which exhibited similar kinetics to previously published
findings (32, 33)), primarily as a result of lower kcat values, with
broadly similarKm values.When considering the enzyme kinet-
ics of the collagenases, it is important to note that APMA-acti-
vated pro-MMPs were utilized; they are not considered to be
fully active with 10–25% of maximal activity typically observed
when compared with MMP-3 activated pro-MMP (34); thus,
the collagenase kinetics for PAR2 may be underrepresented
comparedwith in vivo cleavage. Furthermore, the abundance of
MMPs is an important consideration as tissues undergoing
active remodeling, such as during cartilage destruction in
arthritis, have high expression levels of MMPs (35–37). Taken
together, these data suggest that the collagenases and matrip-
tase can bind PAR2 with broadly similar affinities, but the col-
lagenases are less efficient at turning over the substrate.
Data presented within the present study demonstrate that
the addition of active MMP-1 to PAR2-expressing cells fol-
lowed by the activation of PAR2 bymatriptase leads to an atten-
uated level of activation, importantly a result not observed
following SLIGKV-NH2 activation. This observation can be
interpreted as cleavage of PAR2 by MMP-1 in a classical dis-
arming mechanism similar to cathepsin G or proteinase 3 dis-
arming of PAR2 (17, 38). Thiswould entail the cleavage of PAR2
at Ser37-Leu38, thus removing the canonical activation site to
leave a disarmed receptor on the surface (as evidenced by full
SLIGKV-NH2 activation).
Cleavage of cell-surface receptors by collagenases has previ-
ously been described, with both MMP-1 (39) and -13 (40)
shown to be able to activate the PAR1 receptor by cleavage at
two amino acids upstream or a single amino acid downstream
of the canonical site, respectively. Furthermore, low levels of
trypsin-activated MMP-1 have been previously described to
up-regulate monocyte chemoattractant protein-1 in A549 cells
(which endogenously express PAR2); however, no mechanism
or cleavage site was described (41).
Both PAR2 (23) and matriptase (10) are expressed at signifi-
cantly higher levels in OA chondrocytes than in normal chon-
drocytes, whichmay contribute to the elevated levels ofMMP-1
andMMP-13 expression observed in the disease (22). We have
previously shown matriptase to induce MMP expression in
explant OA cartilage (10), and herein we show that PAR2 acti-
vation in chondrocytes leads to the expression and secretion of
both these collagenases. To our knowledge, the expression of
MMP-1 and MMP-13 in chondrocytes following PAR2 activa-
Figure 5. Activation of PAR2 by the canonical activator peptide SLIGKV-NH2 results inMMP1,MMP13, and ATF3 expression. SW1353-PAR2 cells (blue
lines) or empty vector control cells (red lines) loadedwith Rhod-4-AM fluorescent calciumprobewere subjected to titrations of 0–10MSLIGKVD-NH2 (injected
at arrow S) followedby 5M ionomycin (injected at arrow Io), and calciummobilizationwasmeasured. Data are presented relative to basal fluorescence (at 0 s)
andare representativeof two independent experiments (eachwithn3 technical replicates) (A). SW1353-PAR2 cellswere stimulatedwith100MSLIGKV-NH2
for the indicated times, andRT-qPCRwasperformed forATF3 (B) andMMP1andMMP13 (C). Data are expressed relative toGAPDHandpresentedas -fold change
compared with basal expression (mean S.D., n 4) and are representative of two independent experiments. SW1353-PAR2 or empty vector control cells
were stimulated with 100 M SLIGKV-NH2 for 48 h, and the conditioned medium was used to perform MMP-1 and MMP-13 ELISAs. Data are presented as
mean  S.D. and are representative of three independent experiments (each with n  6 technical replicates) (D). Selected statistical comparisons were
performedusing Student’s two-tailed unpaired t tests against basal (unstimulated)where *** indicatesp 0.001, ** indicatesp 0.01, and * indicatesp 0.05
for MMP1 and ATF3 and ### indicates p  0.001, ## indicates p  0.01, and # indicates p  0.05 for MMP13. All error bars represent S.D. AFU, arbitrary
fluorescence units.
MMPs antagonize PAR2 signaling
J. Biol. Chem. (2019) 294(26) 10266–10277 10271
tion is a novel observation, although the addition of SLIGKV-
NH2 to OA cartilage has previously been shown to increase
MMP-1 and MMP-13 immunostaining (22). Aside from the
collagenases, other MMPs, including MMP-2 (42), MMP-3
(43), andMMP-9 (44), have been shown to be induced by PAR2
activation in various cell types.
Biased agonism following activator peptide stimulation of
PAR2 has previously been explored. The peptide SLAAAA-
NH2 has been shown to induce ERK1/2 phosphorylation in the
absence of calcium mobilization (45) as observed with LIG-
KVD-NH2 in the present study. In rat PAR2, ALIGRL-NH2
peptide (based on the rat canonical activation sequence, SLI-
GRL) has been shown to result in detectable canonical PAR2
activation (as measured by calcium mobilization) with no
detectable activation when substituting the P2 leucine for ala-
nine (SAIGRL-NH2), identifying a key role for the P2 leucine in
canonical activation (46). In the present study, this P2 leucine
becomes the P1 leucine, and no calcium mobilization was
detected. Furthermore, the presence of a basic amino acid in
P5 has been postulated as a requirement for calciummobiliza-
tion (47), which is lost in LIGKVD compared with SLIGKV
(underlined). Data presented within the present study sug-
gest competitive binding in the extracellular region of PAR2
between the two similar sequences, SLIGKV and LIGKVD,
Figure 6. LIGKVD-NH2 is not a canonical PAR2 activator. SW1353-PAR2 cells (blue lines) or empty vector control cells (red lines) loaded with Rhod-4-AM
fluorescent calcium probe were subjected to titrations of 0–100 M LIGKVD-NH2 (left panel) or DVKGIL-NH2 (right panel) and injected at arrow L or D, respec-
tively, followed by 5M ionomycin (injected at arrow Io), and calciummobilizationwasmeasured. Data are presented relative to basal fluorescence (at 0 s) and
are representativeof two independentexperiments (eachwithn3 technical replicates) (A). SW1353-PAR2cellswere stimulatedwith100MSLIGKV-NH2, 100
M LIGKVD-NH2, 100 M DVKGIL-NH2, or 50 nM matriptase for 90 min (left panel) or 24 h (right panel), and RT-qPCR was performed for ATF3 orMMP1. Data are
expressed relative toGAPDH andpresented as -fold change comparedwith basal expression (mean S.D., n 6) and are representative of three independent
experiments (B). SW1353-PAR2 or empty vector control cells were stimulated with 100M SLIGKV-NH2 (C), 100M LIGKVD-NH2 (D), or 100M DVKGIL-NH2 (E)
for the indicated times, and then cell lysates were immunoblotted for phospho-ERK1/2 (p-ERK1/2), ERK1/2, phospho-p38 (p-p38), or p38. Combined densito-
metric scans of three independent experiments (mean S.D.) are presented. Statistical comparisons were performed using Student’s two-tailed unpaired t
tests comparing stimulated cells with basal where *** indicates p  0.001, ** indicates p  0.01, and * indicates p  0.05. All error bars represent S.D. AFU,
arbitrary fluorescence units.
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despite their differing downstream effects. The functional
consequences of ERK1/2 phosphorylation induced by the
collagenase-derived peptide requires further investigation,
although this does not involve the activation of canonical
PAR2 signaling pathways or downstream induced genes
such asATF3 andMMP1. The data presented herein support
a mechanism by which collagenolytic MMPs, the expres-
sion of which is induced by canonical PAR2 activation, neg-
atively regulate PAR2 by abrogating its canonical activation
(Fig. 8).
Experimental procedures
Materials
Unless stated otherwise, all chemicals were of the highest
purity available and obtained from Sigma-Aldrich. All pro-
teins were recombinant human except cathepsinG and neutro-
phil elastase, which were purified from human sputum (Elastin
Products, Owensville, MO). Matriptase (11), hepsin (12),
and pro-MMP-1 and pro-MMP-13 (48) were all prepared as
described previously. Pro-MMP-8 was obtained from R&D
Biosystems (Abingdon, UK). Tissue inhibitor of metalloprotei-
nases-1 (TIMP-1) was a kind gift from Prof. Hideaki Nagase
(Oxford University, UK). The SLIGKV-NH2 peptide was pur-
chased from Abcam (Cambridge, UK), Abz-Ser-Lys-Gly-Arg-
Ser-Leu-Ile-Gly-Tyr(NO2) substrate was from GL Biochem
(Shanghai, China), and peptides LIGKVD-NH2 and DVKGIL-
NH2 were synthesized by Peptide Synthetics (Fareham, UK).
TheMMP inhibitor GM6001 was fromMerckMillipore (Wat-
ford, UK).
Cell culture
SW1353 chondrosarcoma cells were purchased from Amer-
icanTypeCultureCollection (catalog numberHTB-94;Manas-
sas, VA). Cells were cultured at 37 °C in DMEM/F-12 medium
supplemented with 2 mM L-glutamine, 100 IU ml1 penicillin,
100 g ml1 streptomycin, and 10% fetal bovine serum (all
Figure 7. MMP-1 is antagonistic to canonical PAR2 activation. SW1353-PAR2 cells were pretreated with either 1000 nM active MMP-1 or serum-free
medium for 120 min prior to the addition of 10 nM matriptase or 100 M SLIGKV-NH2 for an additional 60 min, and RT-qPCR was performed for ATF3 (A).
SW1353-PAR2 or empty vector control cells were stimulated with either 1000 nM active MMP-1 or 100 M SLIGKV-NH2 for 60 min, and RT-qPCR was
performed for ATF3 (B). SW1353-PAR2 cells were pretreated with 100 M LIGKVD-NH2 or serum-free medium for 120 min prior to the addition of 100 M
SLIGKV-NH2 for an additional 60 min, and RT-qPCR was performed for ATF3 (C). SW1353-PAR2 cells were pretreated with 100 M DVKGIL-NH2 or
serum-free medium for 120 min prior to the addition of 100 M SLIGKV-NH2 for an additional 60 min, and RT-qPCR was performed for ATF3 (D). Data are
expressed relative toGAPDH and presented as -fold change comparedwith basal expression (mean S.D., n 6) and are representative of at least three
independent experiments. Selected statistical comparisons were performed using Student’s two-tailed unpaired t tests where *** indicates p 0.001.
All error bars represent S.D.
MMPs antagonize PAR2 signaling
J. Biol. Chem. (2019) 294(26) 10266–10277 10273
fromThermo Fisher, Paisley, UK). Cells were starved in serum-
free medium for at least 6 h prior to stimulation.
Lentivirus generation and transduction
The lentiviral expression plasmid pSIEW-hPAR2 was con-
structed using a BamHI-tagged humanPAR2PCRproduct gen-
erated from the human PAR2 VersaClone cDNA (RDC0166,
R&DBiosystems) with the primers 5-AAAAGGATCCGCCA-
CCATGCGGAGCCCCAGC-3 (forward) and 5-GCGCG-
GCCGCGGATCCTCAATAGGAGGTCTTAACAGTGGTT-
GAAC-3 (reverse) prior to routine subcloning into BamHI-
digested pHR-SINcPPT-SIEW (a generous gift from Prof. Olaf
Heidenreich, Newcastle University, UK). Lentiviruses were
generated in HEK293T cells following transfection with
pSIEW-hPAR2, pCMV8.91, and pVSV-G (the latter two sup-
plied by Prof. Heidenreich, Newcastle University, UK) accord-
ing to standard protocols and concentrated using the Lenti-X
kit (Clontech).
SW1353 cells at 50% confluence were transduced for 48 h
with lentivirus in serum-containing DMEM/F-12 supple-
mented as above with the addition of 4 g ml1 Polybrene at a
1:200 concentrated virus:medium ratio. Cells were assessed for
successful transduction by examining GFP expression using
inverted fluorescencemicroscopy and then serum-starved for a
minimum of 6 h prior to use.
Peptide digestion and visualization
A 42-amino-acid peptide corresponding to amino acids
31–72 of humanPAR2 (H2N-RSSKGRSLIGKVDGTSHVTGK-
GVTVETVFSVDEFSASVLTGK-COOH) was synthesized (see
supporting methods) (PAR231–72 peptide). The peptide was
incubated at a final concentration of 10Mwith various protei-
nases at 37 °C for varying durations (see supporting methods
for full details of incubation buffers).
For visualization, samples were resolved on 20% polyacryl-
amide Tris-Tricine gels (49), which were subsequently fixed for
1 h in 12%TCA, 30%methanol followed by silver staining using
a Plus One silver staining kit (GE Healthcare) according to the
manufacturer’s instructions. Analytical reversed-phase HPLC
and infusion electrosprayMSwere performed as described pre-
viously (50)with somemodifications (see supportingmethods).
Enzyme kinetics
Pro-MMPs were activated with 1mMAPMA and then active
site–titrated with TIMP-1 (51) using Mca-Lys-Pro-Leu-Gly-
Leu-Dpa-Ala-Arg-NH2 (FS-6; Sigma-Aldrich) as substrate.
Matriptase was titrated using 4-methylumbelliferyl 4-guanidi-
nobenzoate hydrochloride as described (11). Michaelis–
Menten kinetic analyses were performed by incubating a fixed
concentration of active site–titrated proteinase (400.4 nM
MMP-1, 172.8 nMMMP-8, 9.01 nMMMP-13, and 1 nMmatrip-
tase) with 0–100 M 2-Abz-SKGRSLIG-Y(NO2) substrate.
Assays were performed in a FLUOstar OPTIMA fluorimeter
(BMG Labtech, Aylesbury, UK) at 37 °C, ex 320 nm, and em
420 nm, ensuring linearity of substrate hydrolysis prior to fur-
ther quantification. Substrate hydrolysis was quantified using a
standard curve representing total substrate hydrolysis at each
concentration. Nonlinear regression analysis was performed to
generate kinetic constants Km and Vmax (GraphPad Prism soft-
ware), and kcat was calculated. Conditioned medium from an
IL-1OSM-stimulated bovine nasal cartilage explant cultures
was generated as described previously (12).
Calciummobilization assay
Following serum starvation of SW1353 cells transduced in
black-walled clear-bottom 96-well plates, cells were washed
with 200l of Hank’s balanced salt solution supplementedwith
20 mM HEPES, pH 7, and 2 mM CaCl2 (HHBS/Ca2). To each
well, 50 l of a 5 M stock solution of the calcium indicator
Rhod-4-AM(SantaCruzBiotechnology,Heidelberg,Germany)
in HHBS/Ca2 supplemented with 2.5 mM probenecid (Santa
Cruz Biotechnology) and 0.02% Pluronic F-127 (Thermo
Fisher) was added and incubated at room temperature in the
dark for 45 min. Cells were then washed with HHBS/Ca2
before incubating at room temperature for 20 min in HHBS/
Ca2 to allow for dye de-esterification.
Assays were performed in a FLUOstar OPTIMA fluorimeter
(BMG Labtech) at 37 °C during which its injection pumps were
each primedwith 2ml of HHBS/Ca2 before priming with 1ml
of test solutions. The test solution in pump A was always at 2	
final concentration, whereas the test solution in pump B was at
3	 final concentration. To perform the assay, each well was
replaced with 30 l of HHBS/Ca2 and placed in the fluorime-
ter programmed to read in single-well mode (readings taken
every second at ex 520 nm and em 590 nm). For each assay, a
10-s baseline was established before a 30-l injection from
pump A and a 90-s incubation followed by a 30-l injection
from pump B.
Activematrixmetalloproteinase-1 production
Purified activeMMP-1 was produced for cell culture work to
avoid addition of APMA on cells. Recombinant human pro-
MMP-1 was expressed in Escherichia coli and refolded from
chaotrope-solubilized inclusion bodies as described previously
Figure 8. Collagenolytic MMPs are induced by PAR2 activation and can
antagonize furtherPAR2activation.Datapresentedwithin this studydem-
onstrate that canonical PAR2 activation is able to induce MMP1 and MMP13
expression and subsequent secretion fromchondrocytes, and the addition of
MMP-1 to chondrocytes prior to canonical proteolytic stimulation results in
an attenuated activation potential of PAR2.
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(52). The refolded proenzyme was purified using an automated
two-step procedure on an ÄKTAxpress system (GE Health-
care): 1) immobilized metal ion affinity chromatography (IMAC)
using a Ni2-charged 5-ml HiTrap IMAC FF column with 50
mM Tris, pH 7.4, 150 mM NaCl, and 10 mM CaCl2 (TNC) as
binding buffer and an elution buffer of TNC supplementedwith
0.5 M imidazole and 2) size-exclusion chromatography (SEC)
performed on a HiLoad 26/60 Superdex 75 prep grade column
with TNC as running buffer. Following incubation with APMA
and MMP-3 (53), the activated MMP-1 was repurified by tan-
dem IMAC-SEC as above. Aliquots of 5 M MMP-1 were
lyophilized from TNC buffer supplemented with 1% (w/v) BSA
and stored at80 °C until required.
Assessment of PAR2 receptor antagonism
Lyophilized active MMP-1 was resuspended to 1 M in
DMEM/F-12 medium supplemented with 10 mM CaCl2 and
subsequently added to cells for the required time.Matriptase or
SLIGKV-NH2 was added at twice the final concentration, and
cells were incubated for the required time at 37 °C prior to RNA
extraction (see below).
Gene expression analyses
RNA was extracted from cells in a 96-well format using
Cells-to-cDNA lysis buffer (Thermo Fisher) according to the
manufacturer’s instructions prior to cDNA synthesis by Molo-
ney murine leukemia virus reverse transcriptase (Thermo
Fisher) according to themanufacturer’s instructions. Real-time
quantitative (q) PCR was performed using TaqMan Fast
Advanced Master Mix with the following cycling conditions
(QuantStudio 3, Thermo Fisher): 2 min at 50 °C, 20 s at 95 °C
followed by 40 cycles of 1 s at 95 °C, and 20 s at 60 °C. Primer
and probe sequences for MMP1, MMP13 (54), and ATF3
(24) were as described previously. GAPDH expression was
measured using forward primer 5-GTGAACCATGAGAAG-
TATGACAAC-3, reverse primer 5-CATGAGTCCTTCCA-
CGATACC-3, and probe FAM-CCTCAAGATCATCAG-
CAATGCCTCCTG-TAMRA.
SDS-PAGE and immunoblotting
Whole-cell lysates were generated using radioimmune pre-
cipitation assay buffer (150 mM sodium chloride, 1.0% Triton
X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH
8.0, 10 mM sodium fluoride, and 1 mM sodium orthovanadate
supplemented with a cOmplete Mini protease inhibitor mix-
ture tablet). Samples were prepared, and SDS-PAGE was per-
formed as described previously (12). Proteins were transferred
to polyvinylidene fluoride membrane using a Trans-Blot SD
semidry transfer cell (Bio-Rad) according to themanufacturer’s
instructions and incubated with primary antibody overnight at
4 °C. Antibodies used were: phospho-p38 (catalog number
4511), phospho-ERK1/2 (catalog number 9101), ERK1/2 (cata-
log number 9102) from Cell Signaling Technology (Danvers,
MA) and p38 (SC-535) from Santa Cruz Biotechnology.
Enzyme-linked immunosorbent assay (ELISA)
Total MMP-1 was measured as described previously (55),
and total MMP-13 was measured using a Human Total
MMP-13DuoSet ELISA kit (R&DBiosystems) according to the
manufacturer’s instructions.
Statistical analyses
Statistical differences between sample groups were assessed
using the Student’s two-tailed unpaired t test where *** indi-
cates p 0.001, ** indicates p 0.01, and * indicates p 0.05.
For clarity, only selected comparisons are presented in some
figures.
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